BioSante Pharmaceuticals' ($BPAX) shares rose 14% on the news its pancreatic cancer vaccine increased survival by around 60%.
Motley Fool's Brian Orelli weighed in on BioSante Pharmaceuticals' $100,000 upfront deal with the John P. Hussman Foundation for melanoma vaccine development, saying he considered the deal less than
Aduro BioTech has gained access to BioSante Pharmaceuticals' GVAX pancreas cancer vaccine and GVAX prostate cancer vaccine through a licensing agreement. The Berkeley, CA-based company plans to
After Dendreon won a historic approval a week ago for Provenge, the world's first therapeutic cancer vaccine, a host of developers started to flag their own therapeutic vaccine programs. But in the
Shares of BioSante Pharmaceuticals surged this morning in pre-market trading after the developer said that a 19-patient study demonstrated the promise of its GVAX leukemia vaccine to mop up the